KBP 042

Drug Profile

KBP 042

Alternative Names: KBP042

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator KeyBioScience
  • Developer KeyBioScience; Nordic Bioscience
  • Class Insulin sensitisers; Peptides
  • Mechanism of Action Amylin receptor agonists; Calcitonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Metabolic disorders

Most Recent Events

  • 28 Jul 2017 KeyBioscience plans a phase II trial for Type-2 diabetes mellitus (NCT03230786)
  • 09 Jun 2017 Pharmacodynamics data from a preclinical trial in Metabolic disorders presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 08 Jun 2017 KBP 042 licensed to Eli Lilly worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top